Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04782076 · ClinicalTrials.gov registry record · Phase 1
A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants
A Phase 1 study, sponsored by Loxo Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT04782076 is a Phase 1 study that has completed, run by Loxo Oncology. The registered enrollment target is 36 participants.
The verdict
NCT04782076, a Phase 1 study, has completed, sponsored by Loxo Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the effect of selpercatinib on the levels of dabigatran in the blood stream and how long it takes the body to remove dabigatran. This study will also look at how safe and well-tolerated of dabigatran when administered in combination with selpercatinib in healthy participants. This study will last approximately 22 to 25 days.
Interventions
- DRUG Selpercatinib
- DRUG Dabigatran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-03-05 |
| Est. Completion | 2021-05-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04782076
The ClinicalTrials.gov registry entry for NCT04782076 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loxo Oncology, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Selpercatinib is the first listed.
NCT04782076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04782076 about?
NCT04782076 is a clinical study titled "A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants". The main purpose of this study is to determine the effect of selpercatinib on the levels of dabigatran in the blood stream and how long it takes the body to remove dabigatran. This study will also look at how safe and well-tolerated of dabigatran when administered in combination with selpercatinib i...
What is the current status of trial NCT04782076?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2021-03-05. Estimated completion is 2021-05-17.
What interventions are being tested in trial NCT04782076?
The interventions under investigation include: Selpercatinib (DRUG), Dabigatran (DRUG).
Who is sponsoring clinical trial NCT04782076?
This trial is sponsored by Loxo Oncology, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.